---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-23-000150"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:41:32.675449+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Centessa doses first subject in registrational PRESent-2 study for SerpinPC in hemophilia B

## Summary
- Dosed first patient in PRESent-2, a Phase 2b registrational study of SerpinPC for hemophilia B without inhibitors.
- Interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of the adaptive design.
- SerpinPC is a subcutaneously administered APC inhibitor; potential first-in-class therapy for hemophilia B.
- Company expects to start registrational PRESent-3 study for hemophilia B with inhibitors later this year.

## SEC filing metadata
- accession: 0001847903-23-000150
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000150/0001847903-23-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790323000150/cnta-20230710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-23-000150
- JSON: https://secwatch.observer/filing/0001847903-23-000150.json
- Plain text: https://secwatch.observer/filing/0001847903-23-000150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.